The goal ofthe Developmental Research Program ofthe M. D. Anderson Cancer Center Prostate SPORE is to fund promising pilot studies in translational prostate cancer research. As in the initial SPORE, the Developmental Research Program in this new proposal will emphasize the support of translational research studies that can generate clinically testable hypotheses to help us reduce the incidence and mortality of prostate cancer or improve the quality of life of prostate cancer patients. The M. D. Anderson Cancer Center Prostate SPORE Administrative Core will solicit Letters of Intent of no more than two pages for innovative translational research from all institutional investigators, including participants in the SPORE Career Development Program. These applications will be screened by the Program Director and Co-Director as well as the Principal Investigator and Co-Principal Investigator according to objective criteria. Investigators of selected applications will be asked to prepare a five-page proposal modeled after an NIH ROl. As appropriate, the Administrative Core will help investigators submitting proposals to formulate translational specific aims and research plans, as many of these investigators will not have expertise in this area. The process will therefore be a major educational activity and will further stimulate the development of innovative translational research concepts. The proposals will be reviewed and prioritized by the SPORE Leaders (principal Investigators, research project leaders, program directors, and core directors). The projects will be funded for 1 year and will be renewable for an additional year. Developmental Research projects will be evaluated ad hoc and annually by the Program Director/Co-Director, SPORE Leaders, Executive Committee, and the combined Internal/External Advisory Board. Fifteen developmental projects were funded in the initial Prostate SPORE. Investigators receiving Developmental Research grants reported 255 publications related to the research (2001-2006) supported by their grants during 2001-2008. A total of 28 externally reviewed grants were funded. Importantly, two investigators who did not have significant roles in the initial SPORE submission are investigators in major projects or cores in the new Prostate SPORE submission: Drs. Lin (Director, Career Development) and Navone (Leader, Project 4;Special Advisor, Project 3;Collaborator, Core C), highlighting the importance of the Developmental Research Program in identifying projects and investigators with potential value for translational research.
The goal ofthe Developmental Research Program ofthe M. D. Anderson Cancer Center Prostate SPORE is to fund promising pilot studies in translational prostate cancer research that can generate clinically testable hypotheses to help us reduce the incidence and mortality of prostate cancer or improve the quality of life of prostate cancer patients.
|Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461|
|Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176|
|Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707|
|Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106|
|Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76|
|Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43|
|Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924|
|Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174|
|Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69|
|Class, Caleb A; Ha, Min Jin; Baladandayuthapani, Veerabhadran et al. (2018) iDINGO-integrative differential network analysis in genomics with Shiny application. Bioinformatics 34:1243-1245|
Showing the most recent 10 out of 217 publications